In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure that MiraVista…
READ MORE →
MiraVista Diagnostics’ article “Pulmonary Histoplasmosis: A Clinical Update” has been published in “Journal of Fungi” as part of the Special Issue “Diagnosis and Treatment of Invasive Pulmonary Fungal Infections.” Read the article. View the PDF.
The second US based multicenter study found high concordance with the MiraVista LFA and EIA and reported higher sensitivity with the EIA. Read more about the US LFA Multicenter Study.
Several studies have recently been published, evaluated the MVista® CE marked Histoplasma urine antigen lateral flow immunoassay. The first study was conducted in Columbia in partnership with the CDC and reported high sensitivity with the MVD LFA. Read more about…
READ MORE →
In compliance with NIAID/NIH guidelines research at MiraVista Diagnostics utilizing synthetic or recombinant DNA is annually reviewed by the MiraVista Institutional Biosafety Committee (IBC). The IBC is made up of internal and external subject matter experts to ensure that MiraVista…
READ MORE →
In order to maintain good business practices, MiraVista Diagnostics is providing a 90-day notice of pending updates to our referral testing customers. Beginning March 1, 2021 MiraVista Diagnostics will transition to an improved MVista® Histoplasma Antigen Quantitative EIA. The new…
READ MORE →
Are You Underdiagnosing Coccidioidomycosis? Capture Additional Cases with Combined Antigen and Antibody Testing. Dear Colleagues, The prevailing method for diagnosis of coccidioidomycosis is serum antibody testing by immunodiffusion (ID) with a sensitivity of 84.2% and specificity of 96.5%, but a…
READ MORE →
Let us earn your trust and your business. Order fungal diagnostic tests today to experience the MiraVista advantage.